Effectiveness of Bilayered Cellular Matrix in Healing of Neuropathic Diabetic Foot Ulcers: Results of a Multicenter Pilot Trial
- 0 Comments
- 4662 reads
Patients with diabetes are at increased risk of developing foot ulcers. Peripheral neuropathy increases the likelihood of foot injury, and peripheral vascular disease reduces normal healing of minor trauma, allowing development of ulcers. It is estimated that 15 percent of patients with type 1 or type 2 diabetes will develop an ulcer on a foot or ankle within the course of the disease.[1,2] Current standard care for diabetic foot ulcers includes removal of mechanical stress, sharp wound debridement, and use of dressings to maintain a moist wound environment. In addition, infections of the wound site must be managed. Rates of healing with standard care are 24 percent after 12 weeks. A majority of patients with failure of wound healing ultimately require surgery or amputation, and ulcers contribute to 85 percent of lower-extremity amputations for patients with diabetes.[4,5] The development of a new foot ulcer by a 40- to 65-year-old man can generate nearly $28,000 in additional cost of care during the two years after diagnosis.
The need to improve the success rate of healing in diabetic ulcers has prompted new therapeutic approaches. Biologic dressings, such as cultured epidermal allografts, can promote healing of a variety of wounds, including burns, venous ulcers, and split-thickness skin graft donor sites.[7–13] Because the allograft cells survive only briefly and do not become a permanent part of the regenerating tissue, the postulated mechanism of action of cultured grafts is stimulation of wound repair through the release of multiple cytokines and matrix components.[15–18]
Bilayered cellular matrix (BCM, OrCel™, Ortec International, New York, New York) is a porous collagen sponge containing cocultured allogeneic keratinocytes and fibroblasts harvested from human neonatal foreskin. This device has been approved for use in the United States (US) by the Food and Drug Administration (FDA) for the treatment of split-thickness donor sites of burn patients and in patients with mitten-hand deformities secondary to recessive dystrophic epidermolysis bullosa (RDEB). BCM is not approved by the FDA for use on diabetic foot ulcers. The objective of the current study was to examine the effectiveness and safety of treatment of diabetic neuropathic foot ulcers using BCM plus standard care compared with standard care alone.
Study population. Patients included in the study were of either sex, between 18 and 85 years old, and had either type 1 or type 2 diabetes that was controlled (defined as no more than one hospitalization in the previous six months due to hyperglycemia, hypoglycemia, or ketoacidosis). Female patients could be neither pregnant nor nursing. Peripheral neuropathy had to be shown by the absence of protective sensation from the 5.07 (10g) monofilament pressure test. Included patients had adequate peripheral circulation (ABI > 0.7 and great toe pressure > 0.6) and glycosylated hemoglobin HbA1C < 12 percent. Patients with immunocompromising disease or other disease or treatments that would interfere with the study treatment were excluded.
To be included, ulcers were Grade 1A as defined by The University of Texas Health Services classification of diabetic wounds. A Grade 1A wound is a superficial ulcer not involving tendon, capsule, or bone, without the presence of infection and ischemia. Included ulcers were located on the plantar surface of the foot, between 1cm2 and 12cm2 in size and present for at least 30 days. Absence of osteomyelitis had to be shown clinically and radiographically (negative probe to bone test, plain film radiographs, and magnetic resonance imaging [MRI] if indicated).
References 1. Reiber GE. Epidemiology of the diabetic foot. In: Levin ME, O’Neal LW, Bowker JH (eds). The Diabetic Foot. Mosby Year Book, Inc., 1993:1–16. 2. American Diabetes Association. Consensus Development Conference on Diabetic Foot Wound Care: April 7–8 1999, Boston, Massachusetts. Diabetes Care 1999;22:1354–60. 3. Margolis D, Kantor J. Healing of diabetic neuropathic foot ulcers receiving standard treatment. Diabetes Care 1999;22:692–5. 4. Little RJ. Infection of the diabetic foot. In: Levin ME, O’Neal LW, Bowker JM (eds). The Diabetic Foot. Mosby Year Book, Inc., 1993:181–98. 5. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990;13:513–21. 6. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999;22:382–7. 7. Hefton JM, Madden MR, Finkelstein JL, Shires GT. Grafting of burn patients with allografts of cultured epidermal cells. Lancet 1983;2:428–30. 8. Madden MR, Finkelstein JL, Staiano-Coico L, et al. Grafting of cultured allogeneic epidermis on second- and third-degree burn wounds on 26 patients. J Trauma 1986;26:955–62. 9. Deluca M. Multicenter experience in the treatment of burns with the autologous and allogeneic cultured epithelium fresh or preserved in a frozen state. Burns 1989;15:303. 10. Leigh IM, Purkis PE, Navsaria HA, Phillips TJ. Treatment of chronic venous ulcers with sheets of cultured allogenic keratinocytes. Br J Dermatol 1987;117:591–7. 11. Phillips TJ, Kehinde O, Green H, Gilchrist BA. Treatment of skin ulcers with cultured epidermal allografts. J Am Acad Dermatol 1989;21:191–9. 12. Teepe RG, Koebrugge EJ, Ponec M, Vermeer BJ. Fresh versus cryopreserved cultured allografts for the treatment of chronic skin ulcers. Br J Dermatol 1990;122:81–9. 13. Blight A, Fatah MF, Datubo-Brown DD, Mountford EM, Cheshire IM. The treatment of donor sites with cultured epithelial grafts. Br J Plast Surg 1991;44:12–4. 14. Thivolet J, Faure M, Demidem A, Mauduit G. Long-term survival and immunological tolerance of human epidermal allografts produced in culture. Transplantation 1986;42:274–80. 15. Barrandon Y, Green H. Cell migration is essential for sustained growth of keratinocyte colonies: The roles of transforming growth factor-alpha and epidermal growth factor. Cell 1987;50:1131–7. 16. Eisinger M, Sadan S, Silver IA, Flick RB. Growth regulation of skin cells by epidermal cell-derived factors: Implications for wound healing. Proc Natl Acad Sci USA 1988;85:1937–41. 17. Stanulis-Praeger BM, Gilchrest BA. Growth factor responsiveness declines during adulthood for human skin-derived cells. Mech Ageing Dev 1986;35:185–98. 18. Teepe RG, Koch R, Haeseker B. Randomized trial comparing cryopreserved cultured epidermal allografts with tulle-gras in the treatment of split-thickness skin graft donor sites. J Trauma 1993;35:850–4. 19. Eisenberg M, Llewelyn D. Surgical management of hands in children with recessive dystrophic epidermolysis bullosa: Use of allogeneic composite cultured skin grafts. Br J Plast Surg 1998;51:608–13. 20. Lavery L, Armstrong D. Classification of diabetic foot wounds. J Foot Ankle Surg 1996;35:528–31. 21. Margolis D, Allen-Taylor L. Diabetic neuropathic foot ulcers, the association of wound size, wound duration, and wound grade on healing. Diabetes Care 2002;25:1835–9.